Sara Lauricella1,2, Silvia Fabris3, Patricia Sylla4. 1. Division of Colon and Rectal Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. lauricella3008@gmail.com. 2. Department of Colon and Rectal Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 E 98th St 14th Fl, Ste D, New York, NY, 10029, USA. lauricella3008@gmail.com. 3. Unit of Medical Statistic and Epidemiology, Department of Medicine, Campus Bio-Medico of Rome University, Rome, Italy. 4. Division of Colon and Rectal Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
BACKGROUND: To date, the optimal management of patients with inflammatory bowel disease (IBD) and flat low-grade dysplasia (fLGD) of the colon or rectum remains controversial. METHODS: A systematic review was reported in accordance with PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Patients diagnosed with fLGD on surveillance endoscopy were pooled from studies published between 2000 and 2020. Advanced neoplasia was defined by the presence of HGD, CRC or small bowel adenocarcinoma detected on subsequent surveillance endoscopy or from examination of resection specimens. We estimated the pooled annual incidence rate of colorectal cancer (CRC) and advanced neoplasia, and the risk factors associated with neoplastic progression. RESULTS: We identified 24 articles and 738 IBD patients were diagnosed with fLGD on endoscopy. Two hundred thirty-six patients (32%) underwent immediate surgery with surgical specimens demonstrating CRC in 8 patients (pooled prevalence, 8.66%; 95% CI 3.58-19.46) and HGD (high grade dysplasia) in 11 patients (pooled prevalence, 13.97%; 95% CI 5.65-30.65). Five hundred-two patients (68%) underwent endoscopic surveillance with 63 patients with fLGD progressing to advanced neoplasia during endoscopic surveillance (38 HGD, 24 CRC and one patient developing small bowel adenocarcinoma). The mean duration of follow-up after fLGD diagnosis was 71 months (10.9-212). The pooled incidence of CRC and advanced neoplasia was 0.5 (95% CI 0.23-0.77) and 1.71 per 100 patient-year (95% CI 0.88-2.54) respectively. The use of corticosteroids and location of fLGD in the distal colon were significantly associated with neoplastic progression. CONCLUSIONS: This study provides a summary incidence rate of CRC and advanced neoplasia in patients with IBD and fLGD to inform surgeons' and endoscopists' decision-making thus reducing potential ineffective treatments.
BACKGROUND: To date, the optimal management of patients with inflammatory bowel disease (IBD) and flat low-grade dysplasia (fLGD) of the colon or rectum remains controversial. METHODS: A systematic review was reported in accordance with PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Patients diagnosed with fLGD on surveillance endoscopy were pooled from studies published between 2000 and 2020. Advanced neoplasia was defined by the presence of HGD, CRC or small bowel adenocarcinoma detected on subsequent surveillance endoscopy or from examination of resection specimens. We estimated the pooled annual incidence rate of colorectal cancer (CRC) and advanced neoplasia, and the risk factors associated with neoplastic progression. RESULTS: We identified 24 articles and 738 IBD patients were diagnosed with fLGD on endoscopy. Two hundred thirty-six patients (32%) underwent immediate surgery with surgical specimens demonstrating CRC in 8 patients (pooled prevalence, 8.66%; 95% CI 3.58-19.46) and HGD (high grade dysplasia) in 11 patients (pooled prevalence, 13.97%; 95% CI 5.65-30.65). Five hundred-two patients (68%) underwent endoscopic surveillance with 63 patients with fLGD progressing to advanced neoplasia during endoscopic surveillance (38 HGD, 24 CRC and one patient developing small bowel adenocarcinoma). The mean duration of follow-up after fLGD diagnosis was 71 months (10.9-212). The pooled incidence of CRC and advanced neoplasia was 0.5 (95% CI 0.23-0.77) and 1.71 per 100 patient-year (95% CI 0.88-2.54) respectively. The use of corticosteroids and location of fLGD in the distal colon were significantly associated with neoplastic progression. CONCLUSIONS: This study provides a summary incidence rate of CRC and advanced neoplasia in patients with IBD and fLGD to inform surgeons' and endoscopists' decision-making thus reducing potential ineffective treatments.
Authors: Thomas A Ullman; Edward V Loftus; Sanjay Kakar; Lawrence J Burgart; William J Sandborn; William J Tremaine Journal: Am J Gastroenterol Date: 2002-04 Impact factor: 10.864
Authors: Joel R Pekow; Jeremy T Hetzel; Jami A Rothe; Stephen B Hanauer; Jerrold R Turner; John Hart; Amy Noffsinger; Dezheng Huo; David T Rubin Journal: Inflamm Bowel Dis Date: 2010-08 Impact factor: 5.325
Authors: Erik Mooiweer; Andrea E van der Meulen-de Jong; Cyriel Y Ponsioen; C Janneke van der Woude; Ad A van Bodegraven; Jeroen M Jansen; Nofel Mahmmod; Willemijn Kremer; Peter D Siersema; Bas Oldenburg Journal: Clin Gastroenterol Hepatol Date: 2015-05-06 Impact factor: 11.382
Authors: Matthew D Rutter; Brian P Saunders; Kay H Wilkinson; Steve Rumbles; Gillian Schofield; Michael A Kamm; Christopher B Williams; Ashley B Price; Ian C Talbot; Alastair Forbes Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Wojciech Blonski; Rabi Kundu; James Lewis; Faten Aberra; Mark Osterman; Gary R Lichtenstein Journal: Scand J Gastroenterol Date: 2008 Impact factor: 2.423
Authors: Michael D Kappelman; Dora K Farkas; Millie D Long; Rune Erichsen; Robert S Sandler; Henrik T Sørensen; John A Baron Journal: Clin Gastroenterol Hepatol Date: 2013-04-17 Impact factor: 11.382
Authors: Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher Journal: BMJ Date: 2021-03-29